Publications 2006

Original Papers

• Engert A, Bredenfeld H, Döhner H, Ho AD, Schmitz N, Berger D, Bacon P, Skacel T, Easton V, Diehl V. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica. 2006; 91(4):546-9.

Reviews

1. Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J. Sekundärneoplasien nach erfolgreicher Primärtherapie des malignen Hodgkin-Lymphoms. Pathologe 27:47-52 (2006)
2. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin – an updated overview. Nat Clin Pract Oncol 3 (3):152-164 (2006)
3. Kober T, Hülsewede H. Bohlius J, Engert A. Fourth Biannual Report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst 98 (8) (2006)
4. Eich HT, Haverkamp U, Engert A, Koch M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin’s lymphoma – a comparison between extended-field and involved-field radiotherapy based on the data from the German Hodgkin Study Group (GHSG). American Journal of Oncology Review 5(3):175-177 (2006)
5. Sasse S, Diehl V, Engert A. Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience. Haematologica reports 2(7):19-22 (2006)
6. Klimm B, Engert A, Diehl V. First-line treatment of Hodgkin’s lymphoma. Current Hematologic Malignancy Reports I:51-59 (2006)
7. Nogová L, Diehl V, Engert A for the GHSG. Nodular lymphocyte predominant Hodgkin’s lymphoma. Current Hematologic Malignancy Reports I:60-65 (2006) 
8. Klimm B, Engert A. New approaches for patients with advanced-stage and relapsed disease. Hematology (EHA Educ program) 3:166-171 (2006)
9. Naumann F, Weingart O, Kruse E, Schulz H, Bohlius J, Hülsewede H, Engert A. Fifth Biannual report of the Cochrane Haematologic Malignancies Group – Focus on Multiple Myeloma. J Natl Cancer Inst 98:2 (2006) 
10. Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother 7(12): 1641-1651 (2006)
11. Nogova L, Rudiger T, Engert A. Biology, Cinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Hematology: 266-272 (2006)
12. Bredenfeld H. Engert A, Diehl V. 25 Jahre Deutsche Hodgkin Studiengruppe – ein Beitrag zur Versorgungsforschung. Der Onkologe 12:337-344 (2006) 
13. Chapuy B, Borchmann P, Engert A, Trümper L. Targeted-Therapie – neue Zielstrukturen und Substanzen in der Behandlung maligner Lymphome. Onkologe 12:651-58 (2006)
14. Krause SW, Schmitz S, Engert A. Leitlinie Morbus Hodgkin. Deutsche Gesellschaft für Hämatologie und Onkologie (DHGO). 2. Oktober (2006)